Literature DB >> 3733147

The activation of C5 in the fluid phase and in the absence of C3 through the classical pathway of the complement system.

H Kitamura, M Tsuboi, K Nagaki.   

Abstract

Unsensitized guinea-pig erythrocytes (Egp) were lysed by a combination of eight isolated, human-derived complement components, Cls, C4, C2, C5, C6, C7, C8 and C9 (Cls-C9exC3), even in the presence of anti-C3. It was determined that a factor was generated in the reaction mixture of Cls, C4, C2, C5 and C6, which had a lytic activity against Egp when C7, C8 and C9 were added. The lytic factor was similar to C56 in the following properties: the activity of the lytic factor decreased when incubated with C7 prior to its reaction with Egp, the lytic factor did not bind to Egp by itself but it did bind in the presence of C7, EDTA did not have any inhibitory effect on the lytic factor, and the activity of the lytic factor was lost by treatment with anti-C5 or anti-C6 but not by treatment with anti-C4. Furthermore, C5a, a cleavage product of C5, was clearly detected in the reaction mixture of Cls, C4, C2 and C5. These findings indicate that C5 can be activated proteolytically into C5a and C5b in the fluid phase solely by the classical pathway C3 convertase, C42, without any participation of C3.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3733147      PMCID: PMC1453482     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  26 in total

1.  The relationship of the hemolytic activity of active C'1s to its TAMe esterase action: a new method of purification and assay.

Authors:  K Nagaki; R M Stroud
Journal:  J Immunol       Date:  1969-02       Impact factor: 5.422

2.  The ninth component of human complement: isolation, description and mode of action.

Authors:  U Hadding; H J Müller-Eberhard
Journal:  Immunology       Date:  1969-06       Impact factor: 7.397

3.  The complement system.

Authors:  M M Mayer
Journal:  Sci Am       Date:  1973-11       Impact factor: 2.142

4.  Molecular analysis of the reaction of C9 with EAC1-8: reaction of C9 with EAC1-8.

Authors:  H Kitamura; S Inai
Journal:  J Immunol       Date:  1974-12       Impact factor: 5.422

5.  Studies of complement complex C5b,6 eluted from--EAC-6: reaction of C5b,6 with EAC4b,3b and evidence on the role of C2a and C3b in the activation of C5.

Authors:  M B Goldlust; H S Shin; C H Hammer; M M Mayer
Journal:  J Immunol       Date:  1974-09       Impact factor: 5.422

6.  Deficiency of the ninth component of complement in man.

Authors:  S Inai; H Kitamura; S Hiramatsu; K Nagaki
Journal:  J Clin Lab Immunol       Date:  1979-04

7.  Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum.

Authors:  R A Nelson; J Jensen; I Gigli; N Tamura
Journal:  Immunochemistry       Date:  1966-03

8.  Purification of the sixth and seventh component of human complement without loss of hemolytic activity.

Authors:  E R Podack; W P Kolb; H J Müller-Eberhard
Journal:  J Immunol       Date:  1976-02       Impact factor: 5.422

9.  Reactive lysis: the complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9.

Authors:  P J Lachmann; R A Thompson
Journal:  J Exp Med       Date:  1970-04-01       Impact factor: 14.307

10.  Lysis of erythrocytes by complement in the absence of antibody.

Authors:  O Götze; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1970-11       Impact factor: 14.307

View more
  2 in total

1.  Absence of complement component 3 does not prevent classical pathway-mediated hemolysis.

Authors:  Lingjun Zhang; Yang Dai; Ping Huang; Thomas L Saunders; David A Fox; Jijun Xu; Feng Lin
Journal:  Blood Adv       Date:  2019-06-25

2.  C3-independent immune haemolysis: mechanism of membrane attack complex formation.

Authors:  H Kitamura; M Tsuboi; K Nagaki
Journal:  Immunology       Date:  1986-09       Impact factor: 7.397

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.